Analysis of the IDH1 codon 132 mutation in brain tumors - PubMed (original) (raw)
. 2008 Dec;116(6):597-602.
doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5.
Affiliations
- PMID: 18985363
- DOI: 10.1007/s00401-008-0455-2
Analysis of the IDH1 codon 132 mutation in brain tumors
Jörg Balss et al. Acta Neuropathol. 2008 Dec.
Abstract
A recent study reported on mutations in the active site of the isocitrate dehydrogenase (IDH1) gene in 12% of glioblastomas. All mutations detected resulted in an amino acid exchange in position 132. We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas. A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%). Primary glioblastomas and other entities were characterized by a low frequency or absence of mutations in amino acid position 132 of IDH1. The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
Similar articles
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Hartmann C, et al. Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25. Acta Neuropathol. 2009. PMID: 19554337 - Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A. Capper D, et al. Acta Neuropathol. 2011 Feb;121(2):241-52. doi: 10.1007/s00401-010-0770-2. Epub 2010 Nov 11. Acta Neuropathol. 2011. PMID: 21069360 - Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. Hartmann C, et al. Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z. Epub 2010 Nov 19. Acta Neuropathol. 2010. PMID: 21088844 - The definition of primary and secondary glioblastoma.
Ohgaki H, Kleihues P. Ohgaki H, et al. Clin Cancer Res. 2013 Feb 15;19(4):764-72. doi: 10.1158/1078-0432.CCR-12-3002. Epub 2012 Dec 3. Clin Cancer Res. 2013. PMID: 23209033 Review. - [Histological and molecular classification of gliomas].
Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C. Figarella-Branger D, et al. Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Rev Neurol (Paris). 2008. PMID: 18565348 Review. French.
Cited by
- Biostructural, biochemical and biophysical studies of mutant IDH1.
McCoy MA, Lu J, Richard Miller F, Soisson SM, Lam MH, Fischer C. McCoy MA, et al. Nat Commun. 2024 Sep 9;15(1):7877. doi: 10.1038/s41467-024-51692-0. Nat Commun. 2024. PMID: 39251618 Free PMC article. - Pathological Evaluation of Diffuse Gliomas Using IDH1 and ATRX in a Resource-Limited Setting.
Chitturi R, Chinnam A. Chitturi R, et al. Cureus. 2024 Jul 27;16(7):e65551. doi: 10.7759/cureus.65551. eCollection 2024 Jul. Cureus. 2024. PMID: 39192927 Free PMC article. - Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.
Carosi F, Broseghini E, Fabbri L, Corradi G, Gili R, Forte V, Roncarati R, Filippini DM, Ferracin M. Carosi F, et al. Cancers (Basel). 2024 Aug 2;16(15):2752. doi: 10.3390/cancers16152752. Cancers (Basel). 2024. PMID: 39123479 Free PMC article. Review. - Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
Richardson TE, Walker JM, Hambardzumyan D, Brem S, Hatanpaa KJ, Viapiano MS, Pai B, Umphlett M, Becher OJ, Snuderl M, McBrayer SK, Abdullah KG, Tsankova NM. Richardson TE, et al. Acta Neuropathol. 2024 Jul 16;148(1):5. doi: 10.1007/s00401-024-02761-7. Acta Neuropathol. 2024. PMID: 39012509 Free PMC article. Review. - Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.
Kim D, Lee SH, Hwang HS, Kim SJ, Yun M. Kim D, et al. Nucl Med Mol Imaging. 2024 Jun;58(4):237-245. doi: 10.1007/s13139-024-00847-4. Epub 2024 Feb 21. Nucl Med Mol Imaging. 2024. PMID: 38932755 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous